Medicare Prescription Drug Price Negotiation Act of 2021

Bill: 117-hr-2071
Sponsor: full_name: Rep. Welch, Peter [D-VT-At Large]
Introduced: 2021-03-18
Policy area: Health
Subjects: Health care costs and insurance

Inflation and prices

Medicare

Prescription drugs

Public contracts and procurement
Latest action: action_date: 2021-03-19
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2021-03-18
action_desc: Introduced in House
text: <p><b>Medicare Prescription Drug Price Negotiation Act of </b><b>2021</b></p> <p>This bill requires the Centers for Medicare &amp; Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding&nbsp;prices for drugs covered&nbsp;under the Medicare prescription drug benefit. Current law prohibits the CMS from doing so.</p>

tv_txt: I 117th CONGRESS 1st Session H. R. 2071 IN THE HOUSE OF REPRESENTATIVES March 18, 2021 Mr. Welch (for himself, Mr. Pocan , Ms. Castor of Florida , Mr. Grijalva , Mr. Lynch , Mr. Gallego , Ms. Wasserman Schultz , Mr. Cicilline , Ms. Pingree , Mr. Ruiz , Ms. McCollum , and Mrs. Carolyn B. Maloney of New York ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate covered part D drug prices on behalf of Medicare beneficiaries.

1. Short title This Act may be cited as the Medicare Prescription Drug Price Negotiation Act of 2021 . 2. Negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries (a) Negotiation by secretary Section 1860D–11 of the Social Security Act ( 42 U.S.C. 1395w–111 ) is amended by striking subsection (i) (relating to noninterference) and inserting the following: (i) Negotiation of Lower Drug Prices (1) In general Notwithstanding any other provision of law, the Secretary shall negotiate with pharmaceutical manufacturers the prices (including discounts, rebates, and other price concessions) that may be charged to PDP sponsors and MA organizations for covered part D drugs for part D eligible individuals who are enrolled under a prescription drug plan or under an MA–PD plan. (2) No change in rules for formularies (A) In general Nothing in paragraph (1) shall be construed to authorize the Secretary to establish or require a particular formulary. (B) Construction Subparagraph (A) shall not be construed as affecting the Secretary's authority to ensure appropriate and adequate access to covered part D drugs under prescription drug plans and under MA–PD plans, including compliance of such plans with formulary requirements under section 1860D–4(b)(3). (3) Construction Nothing in this subsection shall be construed as preventing the sponsor of a prescription drug plan, or an organization offering an MA–PD plan, from obtaining a discount or reduction of the price for a covered part D drug below the price negotiated under paragraph (1). (4) Semi-annual reports to Congress Not later than June 1, 2022, and every 6 months thereafter, the Secretary shall submit to the Committees on Ways and Means, Energy and Commerce, and Oversight and Government Reform of the House of Representatives and the Committee on Finance of the Senate a report on negotiations conducted by the Secretary to achieve lower prices for Medicare beneficiaries, and the prices and price discounts achieved by the Secretary as a result of such negotiations. . (b) Effective date The amendment made by subsection (a) shall take effect on the date of the enactment of this Act and shall first apply to negotiations and prices for plan years beginning on January 1, 2022.